Andrew Napoli

747 total citations
23 papers, 597 citations indexed

About

Andrew Napoli is a scholar working on Immunology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew Napoli has authored 23 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 8 papers in Molecular Biology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew Napoli's work include Psoriasis: Treatment and Pathogenesis (11 papers), Autoimmune Bullous Skin Diseases (5 papers) and Dermatology and Skin Diseases (4 papers). Andrew Napoli is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (11 papers), Autoimmune Bullous Skin Diseases (5 papers) and Dermatology and Skin Diseases (4 papers). Andrew Napoli collaborates with scholars based in United States, Japan and Germany. Andrew Napoli's co-authors include Richard H. Ebright, Kathleen Boesze‐Battaglia, Catherine L. Lawson, Helen M. Berman, Yuqing Guo, Om P. Lamba, Santosh Kumar Sinha, Jens J. Birktoft, Sergei Borukhov and Stefan G. Sarafianos and has published in prestigious journals such as Cell, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Andrew Napoli

21 papers receiving 593 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Napoli United States	11	295	111	92	89	80	23	597
Frank Striebel Switzerland	13	753 2.6×	92 0.8×	97 1.1×	10 0.1×	74 0.9×	16	958
Dario Oliveira Passos United States	17	624 2.1×	61 0.5×	47 0.5×	16 0.2×	275 3.4×	23	861
Laura Janocko United States	14	305 1.0×	49 0.4×	254 2.8×	10 0.1×	175 2.2×	25	872
Christopher P. Loo United States	14	124 0.4×	511 4.6×	27 0.3×	18 0.2×	114 1.4×	22	833
André A. Pilon United States	9	673 2.3×	264 2.4×	28 0.3×	42 0.5×	273 3.4×	11	1.1k
Dmytro Kovalskyy United States	15	344 1.2×	87 0.8×	28 0.3×	13 0.1×	255 3.2×	25	671
Nicole Prada United States	14	285 1.0×	332 3.0×	43 0.5×	40 0.4×	198 2.5×	16	839
Edwige Col France	13	597 2.0×	104 0.9×	78 0.8×	11 0.1×	87 1.1×	17	794
Jeffrey R. Schneider United States	10	345 1.2×	104 0.9×	47 0.5×	8 0.1×	58 0.7×	21	612
Jan Schultz Switzerland	15	290 1.0×	223 2.0×	101 1.1×	5 0.1×	53 0.7×	19	677

Countries citing papers authored by Andrew Napoli

Since Specialization

Citations

This map shows the geographic impact of Andrew Napoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Napoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Napoli more than expected).

Fields of papers citing papers by Andrew Napoli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Napoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Napoli. The network helps show where Andrew Napoli may publish in the future.

Co-authorship network of co-authors of Andrew Napoli

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Napoli. A scholar is included among the top collaborators of Andrew Napoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Napoli. Andrew Napoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okubo, Yukari, Akimichi Morita, Shinichi Imafuku, et al.. (2025). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO ‐4 Trial. The Journal of Dermatology. 52(6). 953–966.

D’Haens, Geert, Silvio Danese, Remo Panaccione, et al.. (2025). Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis. Journal of Crohn s and Colitis. 19(6).

Gold, Linda Stein, Andrew Blauvelt, Leon Kircik, et al.. (2024). Efficacy of Deucravacitinib in Moderate to Severe Scalp Psoriasis: Analysis of Complete Clearance of Scalp Disease and Symptoms. SKIN The Journal of Cutaneous Medicine. 8(6). s430–s430. 1 indexed citations

Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2024). Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. British Journal of Dermatology. 190(5). 668–679. 35 indexed citations

Imafuku, Shinichi, Yukari Okubo, Yayoi Tada, et al.. (2024). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial. The Journal of Dermatology. 51(3). 365–379. 23 indexed citations

Tada, Yayoi, April W. Armstrong, Shinichi Imafuku, et al.. (2024). Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient‐reported outcomes in the POETYK PSO‐4 study. The Journal of Dermatology. 52(2). 353–358. 1 indexed citations

Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2023). Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 7(2). s118–s118. 3 indexed citations

Papp, Kim, Kenneth B. Gordon, Bruce Strober, et al.. (2023). Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary. JAMA Dermatology. 160(2). 204–204. 3 indexed citations

Armstrong, April W., Richard B. Warren, Howard Sofen, et al.. (2022). 34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials. Journal of the American Academy of Dermatology. 87(3). AB156–AB156. 2 indexed citations

10.

Thaçi, Diamant, Bruce Strober, Kenneth B. Gordon, et al.. (2022). Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 12(2). 495–510. 38 indexed citations

11.

Lara‐González, Samuel, Ana Carolina Dantas Machado, Andrew Napoli, et al.. (2020). The RNA Polymerase α Subunit Recognizes the DNA Shape of the Upstream Promoter Element. Biochemistry. 59(48). 4523–4532. 12 indexed citations

12.

Kwo, Paul Y., Michael Fried, K. Rajender Reddy, et al.. (2018). Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort. Hepatology Communications. 2(4). 354–363. 8 indexed citations

13.

Yin, Michael T., Ellen S. Chan, Todd T. Brown, et al.. (2017). Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation. AIDS. 31(17). 2337–2344. 3 indexed citations

14.

Overton, Edgar T., Ellen S. Chan, Todd T. Brown, et al.. (2015). Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation. Annals of Internal Medicine. 162(12). 815–824. 96 indexed citations

15.

Napoli, Andrew, et al.. (2014). No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. Journal of the International AIDS Society. 17(1). 19214–19214. 29 indexed citations

16.

Locasale, Jason W., Andrew Napoli, Shengfeng Chen, Helen M. Berman, & Catherine L. Lawson. (2009). Signatures of Protein-DNA Recognition in Free DNA Binding Sites. Journal of Molecular Biology. 386(4). 1054–1065. 36 indexed citations

17.

Napoli, Andrew, Catherine L. Lawson, Richard H. Ebright, & Helen M. Berman. (2006). Indirect Readout of DNA Sequence at the Primary-kink Site in the CAP–DNA Complex: Recognition of Pyrimidine-Purine and Purine-Purine Steps. Journal of Molecular Biology. 357(1). 173–183. 43 indexed citations

18.

Tuske, Steven, Stefan G. Sarafianos, Xinyue Wang, et al.. (2005). Inhibition of Bacterial RNA Polymerase by Streptolydigin: Stabilization of a Straight-Bridge-Helix Active-Center Conformation. Cell. 122(4). 541–552. 164 indexed citations

19.

Boesze‐Battaglia, Kathleen, et al.. (2000). A peptide analogue to a fusion domain within photoreceptor peripherin/rds promotes membrane adhesion and depolarization. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1463(2). 343–354. 24 indexed citations

20.

Boesze‐Battaglia, Kathleen, Om P. Lamba, Andrew Napoli, Santosh Kumar Sinha, & Yuqing Guo. (1998). Fusion between Retinal Rod Outer Segment Membranes and Model Membranes: A Role for Photoreceptor Peripherin/rds. Biochemistry. 37(26). 9477–9487. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact